<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969641</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00101707</org_study_id>
    <nct_id>NCT03969641</nct_id>
  </id_info>
  <brief_title>Safety of RIV4 Versus IIV4 in Pregnant Women</brief_title>
  <official_title>A Prospective, Randomized, Clinical Trial to Compare Adverse Birth Outcomes in Pregnant Women Receiving Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized clinical trial. During the study, pregnant women will be&#xD;
      randomized (1:1) to receive RIV4 or IIV4. Vaccines will be administered by licensed&#xD;
      providers.&#xD;
&#xD;
      Prior influenza vaccine history will be verified by medical record review when possible.&#xD;
&#xD;
      Injection-site (local) and systemic reaction data will be assessed on vaccination day and&#xD;
      during the 8 days following vaccination using either identical web-based or paper diaries,&#xD;
      depending on study participant preference.&#xD;
&#xD;
      Maternal serum samples will be collected for antibody titers relevant to Influenza at time&#xD;
      points that include: prior to vaccination and ~29 days post vaccination. When feasible,&#xD;
      maternal blood at delivery and cord blood serum will be analyzed for the same antibody&#xD;
      titers.&#xD;
&#xD;
      Pregnant women will be followed through delivery with comprehensive obstetric and neonatal&#xD;
      outcomes obtained from medical record review for 90 days of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Actual">September 29, 2021</completion_date>
  <primary_completion_date type="Actual">September 29, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse birth outcomes in pregnant women vaccinated with RIV4 versus IIV4</measure>
    <time_frame>12 months</time_frame>
    <description>As measured by the proportion of women experiencing one of the following:&#xD;
Adverse birth outcome is a composite of occurrence of at least one of the following: preterm birth, spontaneous abortion, fetal death, or neonatal death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm birth after RIV4 versus IIV4 vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>As measured by proportions of preterm birth after RIV4 versus IIV4 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined fetal and neonatal death after RIV4 versus IIV4 vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>As measured by proportions of combined fetal and neonatal death after RIV4 versus IIV4 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous abortion after RIV4 versus IIV4 vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>As measured by proportions of spontaneous abortion after RIV4 versus IIV4 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnant women with moderate/severe solicited reactogenicity events (local and systemic) within 8 days after vaccination with RIV4 versus IIV4</measure>
    <time_frame>8 days</time_frame>
    <description>As measured by proportions of moderate/severe solicited reactogenicity events in pregnant women vaccinated with RIV4 versus IIV4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">383</enrollment>
  <condition>Safety</condition>
  <condition>Adverse Event Following Immunisation</condition>
  <condition>Birth Outcomes</condition>
  <arm_group>
    <arm_group_label>RIV4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIV4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Recombinant Influenza Vaccine</intervention_name>
    <description>The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology</description>
    <arm_group_label>RIV4</arm_group_label>
    <other_name>Flublok Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <description>Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.</description>
    <arm_group_label>IIV4</arm_group_label>
    <other_name>Flulaval</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant, as determined by medical history&#xD;
&#xD;
          2. Age ≥ 18 years of age at enrollment&#xD;
&#xD;
          3. Intention of receiving influenza vaccine based on ACIP-CDC guidelines&#xD;
&#xD;
          4. Willing to provide written informed consent prior to initiation of any study&#xD;
             procedures&#xD;
&#xD;
          5. Gestational age at vaccination ≤ 34 weeks 0 days based on reconciliation of last&#xD;
             menstrual period and ultrasound dating. Estimated due date (EDD) and Gestational Age&#xD;
             (GA-EDD) will be based on reconciliation of &quot;sure&quot; first day of the last menstrual&#xD;
             period (LMP) and earliest dating ultrasound. If the LMP is uncertain, then the&#xD;
             earliest dating ultrasound will be used to determine EDD and GA. If the ultrasound&#xD;
             derived-EDD is in agreement with sure-LMP derived EDD, then the LMP-derived EDD is&#xD;
             used to determine GA. If the ultrasound derived EDD is not in agreement with the&#xD;
             LMP-derived EDD, the ultrasound-derived EDD is used to determine GA.&#xD;
&#xD;
          6. English or Spanish literate&#xD;
&#xD;
          7. Intention of being available for entire study period and complete all relevant study&#xD;
             procedures, including follow-up phone calls and collection of delivery information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Influenza vaccine receipt during 2019-2020 or 2020-2021 influenza season prior to&#xD;
             study enrollment.&#xD;
&#xD;
          2. Participation in this study in 2019-2020 influenza season&#xD;
&#xD;
          3. Any condition that may interfere with assessment of local injection site reactions,&#xD;
             e.g. obscuring tattoos&#xD;
&#xD;
          4. Known or suspected immunosuppression as a result of an underlying illness or treatment&#xD;
&#xD;
          5. Use of anti-cancer chemotherapy or radiation therapy within the preceding 36 months&#xD;
&#xD;
          6. Use of oral or parenteral corticosteroids (≥ 20mg/day prednisone equivalent) or&#xD;
             high-dose inhaled glucocorticoid for ≥ 14 consecutive days within the preceding 30&#xD;
             days&#xD;
&#xD;
          7. Has an active neoplastic disease (excluding non-melanoma skin cancer), a history of&#xD;
             any hematologic malignancy, current bleeding disorder, or taking anticoagulants (a&#xD;
             daily aspirin is acceptable)&#xD;
&#xD;
          8. Has a history of receiving immunoglobulin or other blood product (with exception of Rh&#xD;
             immunoglobulin) within the 3 months prior to study vaccination.&#xD;
&#xD;
          9. History of febrile illness (&gt; 100.4°F or 38°C) within the past 24 hours prior to study&#xD;
             vaccination&#xD;
&#xD;
         10. Contraindication to IIV or RIV receipt including history of severe allergic reaction&#xD;
             after a previous dose of any influenza vaccine; or to a vaccine component, including&#xD;
             egg protein&#xD;
&#xD;
         11. History of Guillain-Barré syndrome within 6 weeks of a prior dose of any influenza&#xD;
             vaccine&#xD;
&#xD;
         12. Receipt of any licensed vaccine within 7 days prior to study vaccination or intention&#xD;
             of receiving any vaccines during 8-day post-vaccination period&#xD;
&#xD;
         13. Receipt of live vaccine during current pregnancy&#xD;
&#xD;
         14. Signs or symptoms of active preterm labor, defined as regular uterine contractions&#xD;
             with cervical change (dilation/effacement)&#xD;
&#xD;
         15. Known multi-fetal gestation or fetal congenital anomaly, e.g. genetic abnormality or&#xD;
             major congenital malformation based on antenatal ultrasound&#xD;
&#xD;
         16. Anyone who is already enrolled or plans to enroll in another randomized clinical trial&#xD;
             with any drug, vaccine or medical device. Co-enrollment in observational or behavioral&#xD;
             intervention studies are allowed at any time&#xD;
&#xD;
         17. Any condition which, in the opinion of the investigators, may pose a health risk to&#xD;
             the participant or interfere with the evaluation of the study objectives.&#xD;
&#xD;
         18. Anyone who is a relative of any research study personnel or is an employee supervised&#xD;
             by study staff&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geeta K Swamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen R Broder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Safety</keyword>
  <keyword>Birth outcomes</keyword>
  <keyword>Flublok</keyword>
  <keyword>Pregnant</keyword>
  <keyword>Influenza</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03969641/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

